Compare Davita Inc (DVA) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Tesla, Inc. — how do they compare? Davita Inc trades at $230.44 (market cap $14.92B), while Tesla, Inc. trades at $398.84 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 99.9× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| DVA | TSLA | |
|---|---|---|
Market Cap | $14.92B | $1.49T |
Sector | Health | Consumer Cyclical |
52-Week High | $235.71 | $489.88 |
52-Week Low | $103.87 | $302.63 |
Enterprise Value | $27.47B | $1.46T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Tesla (TSLA) trades at $394.76, down 3.18% over 24 hours, with a bearish technical outlook as it tests support near $391. The stock faces valuation concerns with a P/E of 363.47 and P/S of 14.3, while recent earnings show mixed results with a Q1 2026 beat but a Q3 2025 miss. Revenue declined to $94.83B in 2025, and net income margin compressed to 3.95%. Positive developments include regulatory approval for driver-assistance software in Europe (Reuters, 2026-04-10) and strong growth in German registrations (Zacks Investment Research, 2026-04-10).
Tesla's investment case balances high growth potential in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $409.26 implies modest upside, but competitive pressures and volatile cash flows warrant caution. Investors should focus on execution of the robotaxi and cheaper EV initiatives for catalysts, while monitoring margin recovery and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
